3 Finished Dosage Generics Maker, Domestic Branded Generics Company and Global Pharma Group Stocks With a Strong Future Roadmap: Strides Pharma Science, Lincoln Pharmaceuticals and Lupin
- October 28, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Strides Pharma Science, Lincoln Pharmaceuticals and Lupin: ROE of 11.6% to 23.8% and FY22 to FY26 revenue CAGR of 9.9% to 15.0%. Prices as of 27 Oct 2026.
Quick Answer
The three finished dosage, brand and global pharma to watch are Strides Pharma Science, Lincoln Pharmaceuticals and Lupin. Their return on equity ranges from 11.6% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Finished dosage, brand and global pharma give investors a way to track businesses that sit close to everyday demand in India. Strides Pharma Science, Lincoln Pharmaceuticals and Lupin cover a finished dosage generics maker, a domestic branded generics company and a global pharma group.
This list covers three finished dosage, brand and global pharma with complete current figures: Strides Pharma Science, Lincoln Pharmaceuticals and Lupin. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Finished Dosage, Brand and Global Pharma?
Finished dosage, brand and global pharma are listed pharmaceutical companies that make finished dosage generics for regulated markets, sell branded generics in India and emerging markets and operate across branded, complex generics and specialty medicines. Their earnings depend on launches, approvals and demand across markets.
Finished Dosage, Brand and Global Pharma at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,093.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Lincoln Pharmaceuticals | 550.05 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Lupin | 1,952 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing finished dosage, brand and global pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in finished dosage, brand and global pharma can use the coming numbers to test whether growth is holding.
Why Do Finished Dosage, Brand and Global Pharma Have a Strong Roadmap in India?
Finished dosage, brand and global pharma have a strong roadmap in India because wider access to affordable medicines, new product launches and steady demand for branded generics keep widening the market for Indian pharmaceutical firms.
- Finished dosages. Generics serve regulated markets.
- Branded generics. Trusted brands support repeat demand.
- Global reach. Approvals open new markets.
Why Strides Pharma Science Features Among These Finished Dosage, Brand and Global Pharma
Among the finished dosage, brand and global pharma on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Lincoln Pharmaceuticals Features Among These Finished Dosage, Brand and Global Pharma
Among the finished dosage, domestic brands and specialty shares on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Lupin Features Among These Finished Dosage, Brand and Global Pharma
Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%.
Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Strides Pharma Science vs Lincoln Pharmaceuticals vs Lupin on Key Financials
The table below sets the three finished dosage, brand and global pharma side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin combines the largest FY26 revenue at Rs 29,039 crore with the fastest revenue growth, a 15.0% compound annual rate. A useful habit with finished dosage, brand and global pharma is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
| Lupin | 6,347 | 8,407 | 32.5% |
Key Risks to Check Before Investing in Finished Dosage, Brand and Global Pharma
Every theme carries risks that deserve a check before any decision. For these finished dosage, brand and global pharma, the main points are: Long-term finished dosage, domestic brands and specialty shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter finished dosage, brand and global pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Finished Dosage, Brand and Global Pharma
Finished dosage, brand and global pharma work best when investors track growth, valuation and return on equity side by side. Strides Pharma Science, Lincoln Pharmaceuticals and Lupin each have a clear plan to expand. Based on the 27 October 2026 close, Strides Pharma Science trades at Rs 1,093.3, Lincoln Pharmaceuticals at Rs 550.05 and Lupin at Rs 1,952. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these finished dosage, brand and global pharma to a watchlist.
Download the Univest iOS App or Univest Android App to track finished dosage, brand and global pharma, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are finished dosage, brand and global pharma?
Ans. Finished dosage, brand and global pharma are listed pharmaceutical companies that make finished dosage generics for regulated markets, sell branded generics in India and emerging markets and operate across branded, complex generics and specialty medicines. Their earnings depend on launches, approvals and demand across markets. This list looks at three of them, Strides Pharma Science, Lincoln Pharmaceuticals and Lupin, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which finished dosage, brand and global pharma are covered in this list?
Ans. This list covers Strides Pharma Science, Lincoln Pharmaceuticals and Lupin. Based on the 27 October 2026 close, Strides Pharma Science traded at Rs 1,093.3, Lincoln Pharmaceuticals at Rs 550.05 and Lupin at Rs 1,952. Their return on equity ranges from 11.6% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 15.0%.
Why do finished dosage, brand and global pharma have a strong future roadmap in India?
Ans. Finished dosage, brand and global pharma have a strong roadmap in India because wider access to affordable medicines, new product launches and steady demand for branded generics keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Finished dosages. Generics serve regulated markets. Branded generics. Trusted brands support repeat demand. Global reach. Approvals open new markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What risks should investors check before buying finished dosage, brand and global pharma?
Ans. Investors should check a few risks before buying finished dosage, brand and global pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of finished dosage, brand and global pharma investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.